An interventional study of Tandem t:slim X2 with Control-IQ Technology in Type1 Diabetes Mellitus, sponsored by University of Virginia. Completed at 1 site in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-05-25.
Sponsored by University of Virginia · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Diabetes Mellitus, Type 1 by University of Virginia — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 1 · University of Virginia.
Among the 73 studies in Diabetes Mellitus, Type 1 by University of Virginia, this one is the 56th largest by enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2017, is one of 58 with no phase, and was the 43rd registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 73 studies in Diabetes Mellitus, Type 1 by University of Virginia are open now, in 1 country. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 21–50 · Healthy volunteers
University of Virginia · Sites in United States
Ages 18–45
University of Virginia · Sites in United States
Ages 18–40
University of Virginia · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 28 across the 64 interventional studies, 24 across the 9 observational. Of the 65 that completed or were terminated, 38 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Virginia is the lead sponsor of 677 studies on the registry; 139 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.
2 of the studies in Diabetes Mellitus, Type 1 by University of Virginia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07351318University of VirginiaEstimating Insulin Sensitivity in Pregnancies With Type 1 Diabetes | 2027-01 |
| NCT05653518University of VirginiaArtificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes | 2027-03-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 73 studies in Diabetes Mellitus, Type 1 by University of Virginia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 36-48 hour admission testing the t:slim X2 with Control-IQ Technology
The objective of the study is for clinical staff to gain experience using the proposed artificial pancreas system named t:slim X2 with Control-IQ Technology and assess usability in a supervised setting prior to initiating home use in a Training protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for the study, a subject must meet the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will use the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
Device: Tandem t:slim X2 with Control-IQ Technology
Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
System Suitability
Technology Acceptance Questionnaire Score Scores are on a Likert Scale of 1-Not at All to 5-Extremely for Ease of Use, Usability and Trust in System Scores.
Time frame: 36-48 hours
| Milestone | Tandem t:Slim X2 With Control-IQ Technology |
|---|---|
| Started | 5 |
| Completed | 5 |
| Not completed | 0 |
Technology Acceptance Questionnaire Score Scores are on a Likert Scale of 1-Not at All to 5-Extremely for Ease of Use, Usability and Trust in System Scores.
| score on a scale | Tandem t:Slim X2 With Control-IQ Technology |
|---|---|
| Ease of Use | 5 (5 to 5) |
| Usefulness | 4.8 (4 to 5) |
| Trust in System | 5 (5 to 5) |
Collected over 48 hours. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tandem t:Slim X2 With Control-IQ Technology | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Age, Continuous(years) | Tandem t:Slim X2 With Control-IQ Technology |
|---|---|
| Mean | 52.8 ± 15.9 |
| Sex: Female, Male(Participants) | Tandem t:Slim X2 With Control-IQ Technology |
|---|---|
| Female | 3 |
| Male | 2 |
| Race (NIH/OMB)(Participants) | Tandem t:Slim X2 With Control-IQ Technology |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Tandem t:Slim X2 With Control-IQ Technology |
|---|---|
| United States | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Dec 2017 to primary completion in Dec 2017, 0 months.
Results were first posted in Feb 2019, 1 year 2 months after primary completion.
Of 845 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's 0 months is below that.
Counting every sponsor, half of 950 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.